Brivaracetam:治疗癫痫部分性发作的辅助新药  

Brivaracetam:a novel adjunctive drug in the treatment of partial-onset seizures

作　　者：张玉[1] 闫荟羽[1] 王婷婷[1] 周微[1] 

机构地区：[1]吉林大学第一医院药学部,长春130021

出　　处：《实用药物与临床》2018年第1期118-120,共3页Practical Pharmacy and Clinical Remedies

摘　　要：Brivaracetam,中文名:布瓦西坦,作为治疗癫痫部分性发作及其他类型癫痫的新一代辅助用药,于2016年1月19日、2月19日相继在欧盟及美国批准上市。本文结合国外近些年相关研究文献进行分析,旨在对布瓦西坦作用机制、给药途径、临床研究、不良反应、适用人群等进行总结,供读者参考使用。Brivaracetam, with Chinese name of BuWaXiTan, as a novel drug used in adjunctive therapy for partial-onset seizures and other kinds of epilepsy, has been approved by EMA in January 19th and successively by U. S. FDA in February 19th in the year of 2016. This study,which has analyzed some related articles from abroad,is aimed to make a summary about pharmacological mechanism, dosage, clinical trials, adverse effect and adaptive population of brivaraeetam,in order to provide a reference to readers.

关 键 词：布瓦西坦 癫痫 临床应用 

分 类 号：R971.6[医药卫生—药品]